Tiziana Life Sciences Ltd. announced broad-based findings on the utility of nasal anti-CD3 mAb in the treatment of intracerebral hemorrhage (ICH). The data using a mouse model of collagenase-induced ICH was presented at the Annual American Academy of Neurology conference. The full presentation can be viewed at until May 14, 2023.

Specifically, the study demonstrated that intranasal anti-CD3 antibody: Reduced ICH injury severity; Improved motor coordination recovery; Improved memory retention and functional recovery; Accelerated hematoma resolution at 7 days after ICH, Reduced neuronal cell death at 7 days after ICH; Reduced BBB leakage at 3 days after ICH; Reduced microgliosis at 7 days after ICH: Reduced microglial at 7 days after ICH. Increased CD4+FoxP3+ and FoxP3+ IL10+ dependent Tregs at the site of hematoma at 7 days after ICH); Increased anti-inflammatory and reduced pro-inflammatory cytokines at the site of hematomoma at 7 days after I CH; Upregulated microglial phagocytic transcriptomic profile at 7 days after ICH and Modulated microglial and astrocyte transcriptomic inflammatory profile after ICH. About Foralumab: Activated T cells play an important role in the inflammatory process.

Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 m Ab represents a novel avenue for treatment of inflammatory human diseases.